LyrArc Article Gist
Just as the drug industry is more getting more dependent on the government with the medicare drug benefit raising the retail drug purchases paid by government to 34% in 2006 from 28% in 2005, the industry is facing more governmental scrutiny, from the FDA, from Congress from the public, and during this election campaign. Rep .Rosa DeLauro, who heads the House appropriations subcommittee that has oversight over FDA funding compares the drug industry to the tobacco industry saying that it requires the same amount of scrutiny. At the same time the drug industry is aware of the changes in the public mood and the recent controversies over drug studies, such as the one on Vytorin and other controversy. It is initiating some voluntary changes, registering clinical trial results, submitting commercials to the FDA before they air, and under pressure from medical journals registering trials before they are performed. A new law will requires and its not clear whether the drug industry is dragging its feet and then making changes when there is increasing public pressure. This is the feeling of the medical journals like the Journal of the Medical Association and the New England Journal of Medicine. JAMA's editors will be keeping up this pressure as they have more articles showing how the drug industry manipulates data and the need for public skepticism of information that comes out of the drug industry. The New England Journal editors expressed the need to publish information that helps doctors get all the available information, and not just the information from the drug industry that makes the drug look better than it really is, such as the information and analysis it provided on antidepressant medications. The chairman of the energy and commerce investigations subcommittee Rep. Stupak, finds the advertising for drugs contains information that cannot be backed up and not true ethically, medically, or legally. As this reflects the public mood look for more investigations in Congress and investigative research by the journals. On the issue of importation of drugs from Canada there is bipartisan support as both Senator McCain and Senator Clinton support importation. Clinton supports legislation that allows the FDA to approve new generic versions of biotech drugs which would lower prices of biotech drugs. And with the US consumer budget facing strains in a recession there will be increasing pressure and demands for relief in the area of drug prices, especially for the elderly and uninsured and from corporate payors. ...

LyrArc Article Gist
Miles White, CEO of Abbott Labs, describes the approach based on 4 P's- people, product, presence and perseverance- that will work best for emerging markets. The idea is to become a citizen of that country or region, with the right mix of local people, product customized for regional preferences, local infrastructure, and perseverance for the long haul. The stakes are huge, as emerging markets are growing rapidly. The pharmaceutical market in India is expected to quadruple from $12 billion today to $50 billion by 2020.

LyrArc Article Gist
IMF Director, Christine Lagarde is critical of the action taken by Thomas Jordan, president of the Swiss National Bank on the exchange rate of the Swiss Franc on Jan 14, 2015. She said it came as a surprise. Lagarde said "certainly what is needed is cooperation, collaboration, communication." It appeared to violate a norm among key central bankers to talk about it before moving ahead, and not surprising markets leading to financial instability.

LyrArc Article Gist
A new arrangement is being tried by pharmaceutical companies like Merck and Pfizer to develop new drugs. This is to have scientists inside major research universities and company scientists work together in searching for new drugs and working through the drug development process in a longer term collaboration arrangement, with scientists in universities learning how to work in a company environment and scientists in companies learning how to work in a university environment. On April 25, 2008 Pfizer invested $14 million in an alliance with 4 universities to study obesity and diabetes. Merck and Harvard are working on drug discovery for cancer, and just signed an agrement to develop treatments for bone disease osteoporosis. Efforts at collaboration would need to address issues like patent disputes, academic publication rights, cultural adjustment for university scientists who now have to work at getting FDA approval through a rigorous process. Policies are being developed to overcome the patent and publication issues and Harvard has hired 40 scientists from large pharmaceutical companies to coach university scientists on drug development....

LyrArc Article Gist
The Swiss National Bank gives up on its effort to maintain Swiss competitiveness by dropping the 2011 peg of 1.2 euros to the franc. That effort was becoming costlier as the central bank piled up hundreds of millions of euros on its balance sheet buying up euros to keep the value of the franc down. Investors have put money into francs as a safe haven since the 2008 financial crisis. By offering negative yields of 0.75% the central bank hoped to limit the damage with a surging franc. The franc went up by 15% on January 15, 2015, with the surprise announcement, and stocks of exporters declined sharply. The immediate decision was taken as the ECB planned to weaken the euro with a large quantitative easing program in its Dec. 22, 2015 meeting. The central bank said - "Recently the divergences between the monetary policies of the major currency areas have increased significantly- a trend that is likely to become even more pronounced." A December Swiss initiative was intended to force the Swiss National Bank to convert much of its foreign exchange holdings into gold, as public criticism of the large euro holdings increased with each currency market intervention. The SNB justified its peg to the euro and currency interventions saying that this gave the country's exporters time to make the transition to a stronger Swiss franc....

LyrArc Article Gist
A study by AARP of 514 brand name and generic drugs between 2005 and 2009, shows that generic drug prices went down an average of 31% during this period, and brand name drug prices went up by 41%. One of the authors of the report says that it is important to look at individual drug prices and not studies showing total spending on drugs, because this is a significant cost for people paying out-of-pocket, It drives up insurance premiums, and pushes retirees into coverage gaps in Medicare Part D drug program. Analysts indicate pharmaceutical companies are increasing prices on drugs before patent expiration to get as much profit before the patents expire.

LyrArc Article Gist
Krugman comments on the Swiss National Bank's decision to give up the peg of 1.20 to the euro made in 2011, and reduce interest rates to a negative 0.75% on Jan. 14, 2015. He points to the dangers of complacency about the deflationary trend in Europe, Japan and the U.S., and deflationary pressures in China in the first quarter of 2015.

LyrArc Article Gist
The ECB's executive board's proposal is for 50 billion euros ($58 billion) in bond buying each month for the next 12 months. The ECB's executive board meets on Jan 20, 2015, to discuss the proposal.